XIAP gene expression and function is regulated by autocrine and paracrine TGF-β signaling
© Van Themsche et al; licensee BioMed Central Ltd. 2010
Received: 27 April 2010
Accepted: 16 August 2010
Published: 16 August 2010
X-linked inhibitor of apoptosis protein (XIAP) is often overexpressed in cancer cells, where it plays a key role in survival and also promotes invasiveness. To date however, the extracellular signals and intracellular pathways regulating its expression and activity remain incompletely understood. We have previously showed that exposure to each of the three TGF-β (transforming growth factor beta) isoforms upregulates XIAP protein content in endometrial carcinoma cells in vitro. In the present study, we have investigated the clinical relevance of TGF-β isoforms in endometrial tumours and the mechanisms through which TGF-β isoforms regulate XIAP content in uterine cancer cells.
TGF-β isoforms immunoreactivity in clinical samples from endometrial tumours was assessed using immunofluorescence. Two model cancer cell lines (KLE endometrial carcinoma cells and HeLa cervical cancer cells) and pharmacological inhibitors were used to investigate the signalling pathways regulating XIAP expression and activity in response to autocrine and paracrine TGF-β in cancer cell.
We have found immunoreactivity for each TGF-β isoform in clinical samples from endometrial tumours, localizing to both stromal and epithelial/cancer cells. Blockade of autocrine TGF-β signaling in KLE endometrial carcinoma cells and HeLa cervical cancer cells reduced endogenous XIAP mRNA and protein levels. In addition, each TGF-β isoform upregulated XIAP gene expression when given exogenously, in a Smad/NF-κB dependent manner. This resulted in increased polyubiquitination of PTEN (phosphatase and tensin homolog on chromosome ten), a newly identified substrate for XIAP E3 ligase activity, and in a XIAP-dependent decrease of PTEN protein levels. Although each TGF-β isoform decreased PTEN content in a XIAP- and a Smad-dependent manner, decrease of PTEN levels in response to only one isoform, TGF-β3, was blocked by PI3-K inhibitor LY294002.
XIAP gene expression and function is positively regulated by exposure to the three TGF-β isoforms in a Smad-dependent manner, similar to constitutive XIAP gene expression which depends on autocrine TGF-β/Smad signalling.
TGF-β (transforming growth factor-beta) is a major regulator of proliferation, survival, migration/invasion and metastasis in cancer cells (reviewed in ). Upon ligand binding, TGF-β receptor I (TGFβ-RI) recruits and phosphorylates Smad2 and Smad3: phosphorylated Smad2 or Smad3 then associate with Smad4 to form heterodimeric complexes that translocate to the nucleus, where they can trigger downstream transcriptional responses . Apart from this canonical Smad signalling pathway, TGF-beta can also activate ERK  and PI3-K  pathways. Most data concerning TGF-β signaling and function comes from studies focusing on TGF-β1. However, three TGF-β isoforms have been identified in mammalian cells: TGF-β1, TGF-β2 and TGF-β3. The three TGF-β isoforms can play redundant roles in cancer cells. However, recent studies have shown that TGF-β isoforms can differentially regulate cancer cell phenotype: in prostate cancer cells for example, TGF-β2, but not TGF-β1, confers resistance to TNFα-induced apoptosis . Similarly, TGF-β3, but not TGF-β1 or TGF-β2, increase the invasiveness of endometrial carcinoma cells in vitro .
XIAP (X-linked inhibitor of apoptosis protein) plays a key antiapoptotic role in endometrial carcinoma cells. This member of the inhibitor of apoptosis protein family can directly inhibit caspases-3, -7, and -9 , and we recently observed that XIAP protects endometrial carcinoma cells against various proapoptotic agents, including TGF-β , TNFα  and chemotherapeutic drugs . We have recently reported that exposure to each of the three TGF-β isoforms increase XIAP protein levels in endometrial carcinoma cells . Our results suggested that TGF-β isoforms differentially activate intracellular signaling pathways in endometrial carcinoma cell: indeed, only TGF-β3 activates PI3-K/Akt pathway and increases XIAP protein levels in a PI3-K-dependent manner in these cells . The different molecular mechanisms through which each TGF-β isoform increases XIAP protein content thus remains to be determined.
We have recently highlighted a new function for XIAP in cancer cells, in promoting polyubiquitination and proteasomal degradation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) . PTEN is a critical tumour suppressor , which negatively regulates pro-survival PI3-K/Akt pathway through its lipid phosphatase activity , and inhibits several regulators of cell cycle progression, including MAPK superfamily member ERK, through its protein phosphatase activity . XIAP-induced degradation of PTEN is thus one of the mechanisms through which cancer cells can achieve successful inactivation of PTEN tumour suppressor function. Cellular factors regulating XIAP-induced degradation of PTEN, however, remain to be identified. We have showed that TGF-β3 induces XIAP-dependent degradation of PTEN : since TGF-β1 and TGF-β2 also increase XIAP levels in cancer cells, but through mechanisms different from TGF-β3 , we hypothesized that, compared to TGF-β3, these isoforms would differently regulate XIAP-induced degradation of PTEN.
In the present study, we have used KLE endometrial carcinoma cell line and HeLa cervical cancer cell line, a widespread model for the study of cancer cell signaling [13, 14], to determine the molecular mechanisms responsible for the upregulation of XIAP by each TGF-β isoform, as well as the consequence on XIAP-induced degradation of PTEN. We have found that autocrine TGF-β signalling as well as exposure to exogenous TGF-β isoforms upregulate XIAP expression at the transcriptional level, in a Smad/NF-κB dependent manner, and promote XIAP-induced proteasomal degradation of PTEN.
In the past, most studies examining the role of TGF-β in cancer progression have focused on TGF-β1 isoform. However, a number of studies have shown that TGF-β2 and TGF-β3 are often expressed in human tumours [15, 16]. Furthermore, the different TGF-β isoforms can sometimes differentially activate signaling pathways in cancer cells, leading to isoform-specific effects on cellular phenotype [5, 6]. Dissecting the differential pathway activation and roles of TGF-β isoforms in cancer cells could foster the identification of specific factors regulating key aspects of tumour progression.
We have found that similar to various other cancer cell types [15, 16], human endometrial tumours contain the three TGF-β isoforms. Since the proteins are detectable in both the epithelial and stromal counterparts of the tumours, they could be responsible for autocrine as well as paracrine signalling in the microenvironment of these tumours. We had previously shown that exposure to TGF-β isoforms increases XIAP protein content in endometrial carcinoma cells , and here we found that the three TGF-β isoforms upregulate XIAP expression, at the mRNA level, in these cells. TGF-β1 had previously been shown to increase XIAP gene expression , but the impact of TGF-β2 and TGF-β3 were unknown. Further, the present study revealed that autocrine TGF-β signaling constitutively promotes XIAP gene expression. To our knowledge, this is the first time a receptor-activated pathway responsible for endogenous production of XIAP by cancer cells is identified. RNAi has allowed us to determine that constitutive as well as exogenous TGF-β-induced XIAP gene expression involves Smad pathway. However, we have found no consensus sequence for Smad binding in the promoter of XIAP, suggesting that Smad transcription factors are not directly responsible for the induction of XIAP gene expression in response to TGF-β. It has been shown that Smad and NF-κB components interact and cooperate to regulate gene expression in response to TGF-β [18–20], and the role of NF-κB in constitutive expression of XIAP is well established . In the present study we also found that upon TGF-β treatment both the components of Smad and NF-κB pathway are activated. Therefore, constitutive XIAP gene expression could be regulated via a TGF-β/Smad/NF-κB pathway.
The present study further demonstrates that regulation of XIAP expression by TGF-β isoforms impacts XIAP function in cancer cells, since each TGF-β isoform promotes XIAP-dependent degradation of PTEN when added exogenously. To produce this effect, the three TGF-β isoforms share a requirement for Smad signaling pathway, consistent with the observation that TGF-βs increase XIAP content via Smad pathway. However, decrease of PTEN protein levels in response to TGF-β3, but not TGF-β1 or TGF-β2, also requires PI3-K activity, in agreement with our observation that PI3-K activity is involved in TGF-β3, but not TGF-β1 or TGF-β2-induced upregulation of XIAP protein . The reason why PI3-K activity is required, in addition to Smad signaling, for TGF-β3 to decrease PTEN protein levels is unknown. Since Akt has been shown to phosphorylate and stabilize XIAP protein , inhibition of PI3-K/Akt activity could be sufficient to reduce the stability of XIAP protein and its interaction with PTEN, leading to decreased ubiquitination and degradation of PTEN . Alternatively, PI3-K activity has been shown to promote nuclear export of PTEN , which could favour interaction of PTEN with XIAP in the cytosol, thus promoting XIAP-induced degradation of PTEN. In fact, PI3-K and Smad pathways may interact to regulate TGF-β3-induced degradation of PTEN protein, since phosphorylated Akt interacts with Smad3 and prevents its phosphorylation and translocation to the nucleus [24, 25]. In this scenario, balance between PI3-K and Smad pathway activities would regulate XIAP expression and XIAP-induced degradation of PTEN, and inhibition of one or the other pathway would be sufficient to block TGF-β3-induced decrease of PTEN protein levels. Above all, the fact that only TGF-β3 induces PI3-K-dependent decrease of PTEN protein levels highlights the isoform-specific nature of TGF-β-induced post-transcriptional regulation of PTEN content.
The present study highlights the presence of the three TGF-β isoforms in clinical samples from endometrial carcinoma, and emphasizes the presence of autocrine TGF-β production and signaling in cancer cells. Autocrine TGF-β signaling constitutively regulates XIAP gene expression, in a Smad-dependent manner. Furthermore, exogenous/paracrine TGF-β signaling also transcriptionally upregulates XIAP content, in an isoform-specific manner. Finally, upregulation of XIAP in response to TGF-β regulates XIAP function on post-transcriptional regulation of PTEN protein content, and autocrine TGF-β signalling regulates compartmentalization of PTEN, probably in a XIAP-dependent manner. Altogether, these observations highlight a new role for TGF-β signaling in the regulation of XIAP gene expression and function.
Cell lines and reagents. Human endometrial carcinoma cell line KLE and human cervical cancer cell line HeLa were purchased from ATCC. KLE cells were maintained in DMEM-F12 medium without HEPES supplemented with 10% FBS and 50 mg/mL gentamycin; HeLa cells were maintained in DMEM-F12 medium supplemented with 2% BGS and 50 mg/mL gentamycin. XIAP plasmid constructs were a kind gift from Dr. Robert G. Korneluk (University of Ottawa Eye Institute, Ottawa, Ont, Canada). All antibodies were from Cell Signaling Technology (Beverly, MA, USA) except for mouse monoclonal anti-actin antibody (Sigma, St-Louis, MO, USA), goat anti-rabbit, HRP-conjugated antibody (Bio-Rad Laboratories, Mississauga, ON, Canada), and anti-TGF-β antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Recombinant TGF-βs were purchased from Calbiochem (San Diego, CA, USA). LY294002 and PD98059 were purchased from Cell Signaling Technology. SB431542 was purchased from Sigma.
Immunofluorescence-based detection of TGF-β1 and TGF-β2 in clinical samples. Preparation and image analysis was performed as previously described . Specificity of anti-TGF-βantibodies had previously been confirmed by checkerboard peptide blocking experiments . Briefly, the working dilution of each antibody (TGF-β1 (sc-146) and TGF-β2 (sc-90) from Santa Cruz Biotechnology) was incubated with a 10-fold excess of blocking peptide (Santa Cruz Biotechnology) overnight at 4°C before staining. In all cases, staining was abolished by homologous peptide but unaffected by pre-incubation with peptides corresponding to other isoforms .
Cell treatments. Cells were seeded in 6 well-plates at the required density to reach approximately 60% confluency after 24 h (0.2 × 106 KLE cells and 0.5 × 106 HeLa cells per well). The following day, medium was changed and replaced with fresh media containing the appropriate treatment.
Western blots. Equal amounts of total cell lysates or subcellular fractions (as determined using Bio-Rad DC protein assay) were separated onto 8-15% polyacrylamide gels and then transferred onto nitrocellulose membranes (Bio-Rad). The membranes were blocked with 5% milk in PBS-0.05% Tween-20 for 1 h at RT, probed with primary antibody (PTEN #9559; XIAP #2042; P-ERK #4377; P-Akt (Ser-473) #7291; Akt #9272; Smad3 #9513; Smad4 #9515; TGF-βRI #3712; all antibodies from Cell Signaling) overnight at 4°C, washed in PBS-0.05% Tween-20 and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Bio-Rad). Detection was performed using SuperSignal West FemtoTM substrate (Pierce, Arlington Heights, IL, USA), as described by the manufacturer.
RNA extraction and RT-PCR analysis. Total RNA was isolated from cells using Trizol Reagent (Invitrogen, Burlington, ON, Canada) according to manufacturer's instructions. First strand cDNA was synthesized from 0.4 μg RNA using MMLV reverse transcriptase (Invitrogen). Primers for PCR amplification of XIAP were 5'-gagaagatgacttttaacagttttga-3' (sense) and 5'-ttttttgcttgaaagtaatgactgtgt-3' (antisense). Primers for amplification of PTEN were 5'-accaggaccagaggaaact-3' (sense) and 5'-gctagcctctggatttgacg-3' (antisense). Primers for amplification of Smad4 were 5'-gttgatggatacgtggaccc-3' (sense) and 5'-acctttgcctatgtgcaacc-3' (antisense). Primers for amplification of GAPDH were 5'-gtcagtggtggacctgacct-3' (sense) and 5'-tgagcttgacaaagtggtcg-3' (antisense). PCR reactions were conducted in a MJ Research Thermal cycler (model PTC-100), using the following parameters: 30 sec. at 94°C, 30 sec. at 58°C, and 1 min. at 72°C, for 35 cycles except for GAPDH (25 cycles). The reaction mixture was size-separated on an agarose gel and visualized using SYBR-SafeTM (Invitrogen) staining upon ultraviolet transillumination.
Transfection with siRNAs. Cells were seeded in 6-well plates at a required density to reach approximately 60% confluency in 24 h (0.2 × 106 KLE cells and 0.5 × 106 HeLA cells per well), and allowed to adhere overnight. The day of experiment, TGF-βRI (5'-ggacccuucauuagaucgctt-3' and 5'-gcgaucuaaugaagggucctc-3'), Smad4 (5'-ggucuuugauuugcgucagtt-3' and 5'-cugacgcaaaucaaagacctt-3') or control (5'-acucuaucugcacgcugacuu-3' and 5'-aagucagcgugcagauagagu-3') siRNAs were mixed with Mirus Trans-it TKO transfection reagent (Fisher Scientific, Ottawa, ONT, Canada) following supplier's instructions and added to the cells (100 nM working concentration). After 8 h-transfection, medium was replaced and plates were incubated for 16 additional hours (total: 24 h) or 40 additional hours (total: 48 h), as indicated in Figure legends, at 37°C before cells were collected.
Transfection with shRNAs. Cells were seeded in 6-well plates at the required density to reach approximately 60% confluency after 24 h. The day of transfection, XIAP shRNAs shRNA (5'-GCCACGCAGTCTACAAATTCT-3') or control (scrambled) shRNA (all shRNA inserted into pGeneClip (SABiosciences, Frederick, MD, USA)) were added to cells using a ratio of 3.6 μL Fugene:1.2 μg DNA/well. After 8 h-transfection, medium was replaced and plates were incubated for 40 additional hours (total: 48 h) at 37°C before cells were collected.
Data were subjected to one-way ANOVA (PRISM software version 3.03; GraphPad, San Diego, CA). Differences between experimental groups were determined by the Tukey's test. Statistical significance was accepted when p < 0.05 and indicated as asterisk above individual graph bars.
This work has been supported by a research grant from CIHR. C. Van Themsche was a holder of post-doctoral fellowships from the Cancer Research Society (CRS) and the Fonds de la recherche en santé du Québec (FRSQ). E. Asselin is Chairholder of the Canada research chair in molecular gyneco-oncology.
- Massague J: TGFbeta in Cancer. Cell. 2008, 134: 215-230. 10.1016/j.cell.2008.07.001PubMed CentralView ArticlePubMedGoogle Scholar
- Attisano L, Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 2002, 296: 1646-1647. 10.1126/science.1071809View ArticlePubMedGoogle Scholar
- Yan Z, Winawer S, Friedman E: Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem. 1994, 269: 13231-13237.PubMedGoogle Scholar
- Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M, Sharma DK, Pagano RE, Leof EB: Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res. 2005, 65: 10431-10440. 10.1158/0008-5472.CAN-05-1522View ArticlePubMedGoogle Scholar
- Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV: Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA. 2004, 101: 7112-7117. 10.1073/pnas.0402048101PubMed CentralView ArticlePubMedGoogle Scholar
- Van Themsche C, Mathieu I, Parent S, Asselin E: Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem. 2007, 282: 4794-4802. 10.1074/jbc.M608497200View ArticlePubMedGoogle Scholar
- Van Themsche C, Lafontaine L, Asselin E: X-linked inhibitor of apoptosis protein levels and protein kinase C activity regulate the sensitivity of human endometrial carcinoma cells to tumor necrosis factor alpha-induced apoptosis. Endocrinology. 2008, 149: 3789-3798. 10.1210/en.2008-0275View ArticlePubMedGoogle Scholar
- Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E: Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 2008, 13: 259-271. 10.1007/s10495-007-0165-6View ArticlePubMedGoogle Scholar
- Van Themsche C, Leblanc V, Parent S, Asselin E: XIAP regulates PTEN ubiquitination, content and compartmentalization. J Biol Chem. 2009, 284: 20462-20466. 10.1074/jbc.C109.009522PubMed CentralView ArticlePubMedGoogle Scholar
- Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997, 15: 356-362. 10.1038/ng0497-356View ArticlePubMedGoogle Scholar
- Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998, 95: 29-39. 10.1016/S0092-8674(00)81780-8View ArticlePubMedGoogle Scholar
- Gu J, Tamura M, Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol. 1998, 143: 1375-1383. 10.1083/jcb.143.5.1375PubMed CentralView ArticlePubMedGoogle Scholar
- Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, Rapp UR, Rajalingam K: X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol. 2008, 10: 1447-1455. 10.1038/ncb1804View ArticlePubMedGoogle Scholar
- Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007, 128: 129-139. 10.1016/j.cell.2006.11.039PubMed CentralView ArticlePubMedGoogle Scholar
- Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima A, Cornelison R: Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat. 2010, 121: 727-735. 10.1007/s10549-009-0590-zPubMed CentralView ArticlePubMedGoogle Scholar
- Soufla G, Porichis F, Sourvinos G, Vassilaros S, Spandidos DA: Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Cancer Lett. 2006, 235: 100-113. 10.1016/j.canlet.2005.04.022View ArticlePubMedGoogle Scholar
- Kaur S, Wang F, Venkatraman M, Arsura M: X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J Biol Chem. 2005, 280: 38599-38608. 10.1074/jbc.M505671200View ArticlePubMedGoogle Scholar
- Kon A, Vindevoghel L, Kouba DJ, Fujimura Y, Uitto J, Mauviel A: Cooperation between SMAD and NF-kappaB in growth factor regulated type VII collagen gene expression. Oncogene. 1999, 18: 1837-1844. 10.1038/sj.onc.1202495View ArticlePubMedGoogle Scholar
- Lopez-Rovira T, Chalaux E, Rosa JL, Bartrons R, Ventura F: Interaction and functional cooperation of NF-kappa B with Smads. Transcriptional regulation of the junB promoter. J Biol Chem. 2000, 275: 28937-28946. 10.1074/jbc.M909923199View ArticlePubMedGoogle Scholar
- DiChiara MR, Kiely JM, Gimbrone MA, Lee ME, Perrella MA, Topper JN: Inhibition of E-selectin gene expression by transforming growth factor beta in endothelial cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med. 2000, 192: 695-704. 10.1084/jem.192.5.695PubMed CentralView ArticlePubMedGoogle Scholar
- Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J: Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998, 188: 211-216. 10.1084/jem.188.1.211PubMed CentralView ArticlePubMedGoogle Scholar
- Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, Cheng JQ: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 2004, 279: 5405-5412. 10.1074/jbc.M312044200View ArticlePubMedGoogle Scholar
- Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK: Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res. 2007, 67: 11054-11063. 10.1158/0008-5472.CAN-07-1263View ArticlePubMedGoogle Scholar
- Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K: Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol. 2004, 6: 366-372. 10.1038/ncb1117View ArticlePubMedGoogle Scholar
- Remy I, Montmarquette A, Michnick SW: PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol. 2004, 6: 358-365. 10.1038/ncb1113View ArticlePubMedGoogle Scholar
- Mason GI, Hamburger J, Bowman S, Matthews JB: Salivary gland expression of transforming growth factor beta isoforms in Sjogren's syndrome and benign lymphoepithelial lesions. Mol Pathol. 2003, 56: 52-59. 10.1136/mp.56.1.52PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.